// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Late-night salivary cortisol (LNSC) levels in a Phase III study of long-acting pasireotide in patients with Cushing's disease (CD)

John Newell-Price - European Congress of Endocrinology (ECE) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Pasireotide

The global, prospective, observational PARADIGHM™ registry for patients with chronic hypoparathyroidism was expanded to capture recombinant human parathyroid hormone, rhPTH(1-84), use under routine clinical care

Bart L Clarke - European Congress of Endocrinology (ECE) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

rhPTH

Long-term efficacy and safety of once-monthly pasireotide in patients with Cushing's disease: A Phase III extension study

Maria Fleseriu - European Congress of Endocrinology (ECE) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Pasireotide

Predictors of response to long-acting pasireotide in patients with Cushing's disease during a Phase III study

Przemysław Witek - European Congress of Endocrinology (ECE) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Pasireotide

Diabetes complications and comorbidities in patients newly diagnosed with diabetes in newfoundland and labrador (NL): gender differences

Richa Parihar - European Congress of Endocrinology (ECE) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Characterization of sex hormone binding globulin ligands with potential to enhance sex steroid action

Phillip Round - European Congress of Endocrinology (ECE) , 2018

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

N/A

Dihydrotestosterone

Proteolytically cleaved forms of corticosteroid-binding globulin with low steroid-binding affinity are not present in human plasma

Lesley Hill - European Congress of Endocrinology (ECE) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Glucocorticoid

CGM Shows Islet Transplantation Prevents Hypoglycemia, Correcting Time in Range and Reducing Glycemic Variability, Despite Subnormal Beta-Cell Function

SHAREEN FORBES - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes

YALING TANG - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Epimorph

Real-World Risk Indicators of Severe Hypoglycemia in T2D—Results of the InHypo-DM Study

ALEXANDRIA RATZKI-LEEWING - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Persistence with Insulin Glargine 300 IU/ml Compared with Other Basal Insulins—A Canadian Retrospective Cohort Study

KOBINA A. QUANSAH - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Insulin glargine

Cognitive Behavioral Intervention Produces Comparable Reductions in Regimen-Related Distress in Insulin Users and Nonusers—Twelve-Month Results from COMRADE

KERRY LITTLEWOOD - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Potentiation of TRPM5 with Stevioside in the Beta Cells Stimulates Insulin Secretion

KOENRAAD PHILIPPAERT - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Initial Clinical Evaluation of VC-01TM Combination Product—A Stem Cell–Derived Islet Replacement for Type 1 Diabetes (T1D)

ROBERT R. HENRY - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Intranasal glucagon

Long Noncoding RNA Zfas1 in Diabetic Cardiomyopathy

BIAO FENG - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Streptozotocin

Sex Differences in Neuropathy and Neuropathic Pain in Long-Standing Diabetes—Results from the Canadian Study of Longevity in Type 1 Diabetes

NANCY CARDINEZ - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Reducing Basal Insulin 90 Minutes before Exercise Protects Against Hypoglycemia Better than Insulin Suspension at Exercise Onset in T1D—The OmniTIME Results

DESSI ZAHARIEVA - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Glycation and Deamidation Result in HDL Dysfunction in Patients with Type 2 Diabetes

TAKHAR KASUMOV - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-3 Expression, and Inflammatory Cell Infiltration in ob/ob Mouse Model

JEAN-CHRISTOPHE SIMARD - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

PBI4050

Autoimmunity in Patients with Type 2 Diabetes in Newfoundland and Labrador

SAHAR J. IQBAL - American Diabetes Association (ADA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved